News | September 16, 2009

Premion First in Australia to Treat Cancer Patients with RapidArc

September 16, 2009 - Cancer patients in Australia have gained access to advanced RapidArc radiotherapy treatments from Varian Medical Systems with its introduction by the leading radiation oncology provider in Queensland.

Premion, which operates five cancer centers in Queensland, has treated more than a dozen prostate cancer patients to date with this fast, precise and efficient technique at its Chermside treatment center in Brisbane.

Dr. James MacKean, Premion's lead radiation oncologist for the RapidArc program, said, "With RapidArc, improved conformality and daily treatment set-up accuracy is combined with dynamic rotational arc treatments, keeping unwanted radiation doses away from nearby structures such as the rectum and bladder. Treatment times are reduced, which improves the overall patient experience."

"RapidArc, which we introduced after extensive testing, is combined with the latest generation Varian treatment machine incorporating advanced image-guidance technology,'' explained senior medical physicist Matthew Murray. "At Premion we have a great team of dedicated radiation therapists and medical physicists to ensure these advanced treatment techniques are delivered to the highest standards."

Premion, which treats cancer patients using ten linear accelerators at its five sites, says its RapidArc program at Chermside will expand to include the treatment of brain, head and neck and lung tumors in the near future.

Premion patient, 68-year-old Bob Major, received RapidArc treatment over an eight week period in July and August. "I found my treatment on the RapidArc-equipped machine excellent, I was in and out of the treatment room in minutes, the Premion staff were very professional and my urologist worked closely with Dr. MacKean to develop my treatment plan," he said.

RapidArc delivers a precise and efficient treatment in single or multiple arcs of the treatment machine around the patient and makes it possible to deliver image-guided intensity modulated radiotherapy (IMRT) two to eight times faster than is possible with conventional IMRT. Faster treatments allow for greater precision, since there is less chance of patient or tumor movement during treatment delivery and, with less time on the treatment couch, also allow for greater patient comfort. Conventional IMRT treatments are slower and more difficult for radiotherapy radiographers because they target tumors using a complex sequence of fixed beams from multiple angles.

"The philosophy of Premion at all five of our locations is to offer Queensland and northern New South Wales patients the full range of state-of-the-art facilities in a friendly, efficient and caring environment," indicated Dr. MacKean. "'We strive to avoid waiting lists and improve patient access."

Stuart Hamilton, Varian's regional sales director, added, "Premion is continually striving to offer more advanced treatments for the benefit of cancer patients and we are delighted to be working with Premion to introduce RapidArc in Australia. Since the introduction of the technique in the US and Europe last year, more than 100 cancer centers worldwide have introduced this approach, improving the patient experience while maximizing treatment precision."

For more information: www.varian.com

Related Content

RayStation Selected for New Carbon Ion Therapy Center in Japan
News | Treatment Planning | January 18, 2018
January 18, 2018 – RayStation has been chosen as the treatment planning system for a new carbon-ion therapy facility
Raysearch Receives First Order for the Raycare Oncology Information System
News | Oncology Information Management Systems (OIMS) | January 18, 2018
January 18, 2018 – Anderson Regional Cancer Center (ARCC) in Meridian, Mississippi, has placed the first order for...
Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
News | Radiation Therapy | January 03, 2018
Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
News | Radiation Therapy | January 02, 2018
IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
FDA Clears GammaPod Stereotactic Radiotherapy System for Breast Cancer Treatment
Technology | Stereotactic Body Radiation Therapy (SBRT) | December 22, 2017
The U.S. Food and Drug Administration (FDA) has cleared the new GammaPod noninvasive stereotactic radiotherapy system...
Overlay Init